What’s behind Trump’s drug pricing proposal? This insight explores key policy tools, global scenarios, and long-term ...

Professor Graham Cookson responds to Chancellor's Spending Review announcement boosting NHS spend by 3%. Earlier today, UK ...

OECD countries formally use QALYs in pricing and reimbursement decisions. See how HTA practices differ and where policies ...

Antimicrobial resistance (AMR) is a global health crisis, projected to cause up to 10 million deaths annually and impose economic costs exceeding $150 billion by 2050.

In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Andrés ...

Pharmacogenomics (PGx) is the study of how genetic variation affects the efficacy and safety of medicines, enabling ...

New OHE insight on immunisation: despite high returns on investment, global spending lags. We outline why and how countries ...

Analysis of Trump’s ‘Most Favoured Nation’ Executive Order on drug pricing, its global impact, price convergence aims, and ...

The UK is confronting a seismic demographic shift with an ageing population and declining fertility rates. In preparing for this change, it is critical that we shift how we think about health across ...